Kura Oncology, Inc. (NASDAQ:KURA – Get Free Report) insider Brian Powl sold 4,345 shares of the business’s stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $11.89, for a total transaction of $51,662.05. Following the sale, the insider directly owned 169,269 shares of the company’s stock, valued at approximately $2,012,608.41. This trade represents a 2.50% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
Kura Oncology Stock Performance
Shares of NASDAQ:KURA traded up $0.51 during midday trading on Monday, reaching $12.40. 2,673,296 shares of the company traded hands, compared to its average volume of 1,620,411. Kura Oncology, Inc. has a 12 month low of $7.36 and a 12 month high of $12.90. The company has a quick ratio of 4.71, a current ratio of 4.73 and a debt-to-equity ratio of 0.12. The firm has a market capitalization of $1.10 billion, a price-to-earnings ratio of -3.68 and a beta of 0.38. The firm’s fifty day moving average price is $10.53 and its two-hundred day moving average price is $9.47.
Kura Oncology (NASDAQ:KURA – Get Free Report) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($0.77) EPS for the quarter, topping the consensus estimate of ($0.88) by $0.11. Kura Oncology had a negative net margin of 384.30% and a negative return on equity of 207.18%. The business had revenue of $20.87 million during the quarter, compared to analyst estimates of $20.16 million. On average, equities analysts expect that Kura Oncology, Inc. will post -3.23 earnings per share for the current year.
Institutional Trading of Kura Oncology
Analyst Ratings Changes
Several research analysts recently issued reports on KURA shares. Raymond James Financial set a $24.00 target price on shares of Kura Oncology in a report on Monday. Wells Fargo & Company set a $24.00 target price on shares of Kura Oncology in a research note on Thursday, June 4th. Wall Street Zen upgraded shares of Kura Oncology from a “strong sell” rating to a “hold” rating in a report on Saturday, May 16th. Citizens Jmp reaffirmed a “market outperform” rating and set a $24.00 target price on shares of Kura Oncology in a research note on Monday. Finally, Morgan Stanley set a $24.00 target price on shares of Kura Oncology in a report on Monday. Ten equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Kura Oncology currently has an average rating of “Moderate Buy” and an average price target of $25.40.
Check Out Our Latest Stock Analysis on KURA
Kura Oncology Company Profile
Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.
The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.
Featured Stories
- Five stocks we like better than Kura Oncology
- Visa Just Put Hims & Hers in the Penalty Box—Here’s Why It Matters
- Treasury Yields Are Surging Again: 3 Stocks That Could Feel the Pain
- Snowflake Could Be Headed for New Highs Despite Insider Selling
- MongoDB Is Surging—And the Next Catalyst Is Almost Here
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
